Jiangsu Hengrui Pharmaceuticals Co., Ltd. 4

What Happened

• Jiangsu Hengrui Pharmaceuticals Co., Ltd., reported as a 10% owner (via wholly owned Hengrui (USA) Ltd.), converted preferred/derivative securities into Kailera common stock on 2026-04-20.
• The Form 4 shows acquisitions of 9,477,719 and 2,034,133 common shares (two "conversion" acquisitions) and corresponding dispositions of derivative securities of 4,968,789 and 708,814 shares recorded at $0.00. The conversions result in a net increase of 5,834,249 common shares held (11,511,852 shares acquired vs. 5,677,603 derivative shares disposed).
• No cash changed hands on the disposal lines — the $0.00 entries reflect conversion/retirement of derivative preferred securities, not an open-market sale.

Key Details

• Transaction date: 2026-04-20; Form 4 filed 2026-04-22 (timely within the Form 4 filing window).
• Reported line items: Acquired 9,477,719 and 2,034,133 common shares (conversion); Disposed 4,968,789 and 708,814 derivative shares at $0.00.
• Shares owned after transaction: Not specified in the reported excerpt.
• Footnotes: (F1) Securities are held directly by Hengrui (USA) Ltd., a wholly owned subsidiary of Jiangsu Hengrui. (F2) The Series A‑2 convertible preferred/non‑voting preferred were convertible into common stock and automatically converted into common immediately prior to the issuer’s IPO.
• Insider type: This is an institutional 10% owner, not an executive—treat as ownership restructuring/IPO-related mechanics rather than an executive trade.

Context

• These entries reflect conversion of preferred/derivative securities into common stock (a corporate/IPO-related event), not market purchases or cash sales. The $0.00 disposal lines represent surrender/retirement of preferred/derivative instruments upon conversion.
• Conversions tied to IPO mechanics are typically neutral for signaling management sentiment; they increase public float but do not indicate an institutional buy or sell in the open market.